ALGS
Aligos Therapeutics, Inc.
There isn't enough reported data to score ALGS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ALGS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ALGS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ALGS PE Valuation
ALGS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ALGS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ALGS's losses to shrink, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ALGS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$46.75 | +$19.75 |
| Q2 2023 | -$47.50 | +$27.50 |
| Q1 2023 | -$48.50 | +$34.50 |
| Q4 2022 | -$56.25 | +$24.25 |
ALGS has the stronger earnings trend. Trailing diluted EPS is down 142% for ALGS versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ALGS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +282% |
| Q1 2026 | $2.8M | +810% |
| Q4 2025 | $169K | -72% |
| Q3 2025 | $741K | -41% |
| Q2 2025 | $965K | -9% |
| Q1 2025 | $311K | -55% |
| Q4 2024 | $606K | -9.8% |
| Q3 2024 | $1.3M | +15% |
ALGS's revenue is recovering but still below its 2023 peak: $3M last quarter, up 282% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -774% | +3054 points |
| Q1 2026 | -952% | +5236 points |
| Q4 2025 | -12908% | -9515 points |
| Q3 2025 | -3827% | -2217 points |
| Q2 2025 | -1924% | +566 points |
| Q1 2025 | -6187% | -3011 points |
| Q4 2024 | -3393% | +475 points |
| Q3 2024 | -1610% | +147 points |
ALGS's operating margin was −774% last quarter, up 1151 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ALGS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ALGS on profitability, with a higher operating margin.
ALGS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5M | +$25.8M |
| Q2 2026 | -$25M | -$9.4M |
| Q1 2026 | -$23.1M | -$2.2M |
| Q3 2025 | -$24.3M | -$4.2M |
| Q2 2025 | -$15.5M | +$4M |
| Q1 2025 | -$20.9M | +$1.8M |
| Q3 2024 | -$20.1M | +$235K |
| Q2 2024 | -$19.5M | -$5.9M |
ALGS has burned cash in almost every quarter: −$68M over the past year, against −$81M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ALGS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ALGS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +31.1K shares |
| 1 year | +1.1% | +111K shares |
| 3 years | +513% | +8.8M shares |
ALGS has 10M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ALGS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ALGS Net Leverage
ALGS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ALGS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 8.1 | Oversold |
ALGS's weekly RSI is 28 (oversold) and its Stochastic is 8 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ALGS PE vs Healthcare Sector
ALGS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ALGS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 57% below |
| 20 week MA | $5.29 | 63% below |
| 50 week MA | $6.56 | 70% below |
| 100 week MA | $9.83 | 80% below |
| 200 week MA | $15.4 | 87% below |
ALGS is in a downtrend: it's below all five of its weekly moving averages, and 87% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ALGS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $371.3 | $721.3 | +94% |
| 2021 | $721.3 | $296.5 | -59% |
| 2022 | $296.5 | $22.7 | -92% |
| 2023 | $22.7 | $16.6 | -27% |
| 2024 | $16.6 | $41.2 | +148% |
| 2025 | $41.2 | $10.1 | -75% |
| 2026 YTD | $10.1 | $1.98 | -80% |
ALGS's yearly returns have swung widely, from +148% in 2024 to −92% in 2022. It's down 80% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ALGS on returns for 2026, with the stronger performance.